Facebook
Twitter
LinkedIn
Forward
Tammy Triglianos, DNP, ANP-BC, AOCNP, and Mary Dunn, MSN, RN, OCN, NP-C, will highlight the multifaceted challenges faced by cancer survivors and emphasize the importance of personalized care. By examining the physical, emotional, and social needs that evolve over time, they will discuss strategies for approaches to care, including interdisciplinary collaboration, to improve quality of life.
|
Oral oncolytics have revolutionized cancer care over the last two decades. Although they provide a more convenient & often more tolerable alternative to traditional chemotherapy agents, their unique mechanisms of action lead to a wide range of potential side effects. In this CPP panel discussion, Aimee Faso, Bianka Patel, and Kevin Chen will discuss the considerations when managing side effects for patients receiving oral oncolytic treatments for various solid tumor and hematologic malignancies.
|
Nancy Vogler, AGPCNP-BC, will discuss the common types of anemia and thrombocytopenia, common causes of each, how the non-hematology provider can best manage patients with anemia and/or thrombocytopenia, and when to refer to hematology.
|
Cancer survivors may face many unique psychosocial challenges. Melissa Holt, DNP, PMHNP-BC and Lisa Kanser, PsyD discuss Acceptance and Commitment Therapy (ACT) is an evidence-based psychotherapeutic approach that can effectively teach patients skills to manage these challenges after completing cancer treatment. We will take you through case vignettes to show you how ACT can be applied to this patient population.
|
Tailored for medical providers, this session led by a physical therapist addresses challenges like speech and swallowing difficulties or pelvic floor issues in gynecological cancer. Explore the pivotal role of physical therapy in survivorship care plans and delve into current research supporting interventions for head and neck, gynecological, breast cancer, and other oncological conditions. Emphasizing interdisciplinary collaboration, we'll discuss the synergy between medical providers and physical therapists in delivering optimal cancer care. Additionally, learn the art of patient education in oncology rehabilitation, empowering medical providers to effectively communicate the role of physical therapy in cancer care.
|
Patients undergoing treatment for cancer utilize many medications that have relevant drug-gene interactions. The use of pharmacogenomic testing can assist with drug selection, drug dosing, and the development of personalized medication monitoring plans. Amber Cipriani, PharmD, BCOP, will describe some common examples of drug-gene interactions relevant to oncology. She will also discuss current efforts to expand the use of pharmacogenomic testing into current clinical practice.
|
Immunotherapy has made tremendous progress as cancer-directed therapy has evolved, particularly in the field of T cell-engaging therapies. Common and serious side effects of these types of therapies include Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). Join us as Bejal Kikani, MSN, FNP-BC, WHNP-BC, discusses the recognition, grading, and treatment of these toxicities.
|
Jeremiah 'Jig' Deneve, DO, FACS, provides an overview of the natural history, treatment, and outcome for peritoneal carcinomatosis.
|
Megan McElfresh, PA-C, will review chimeric antigen receptor therapy, associated side effects, and the treatment or prevention of side effects.
|
This multidisciplinary Panel Presentation will describe the importance of CT-based lung cancer screening, indications and criteria for screening, the optimal structure and requirements of a screening program, and the current state of screening at UNC. We will present practical information relevant to providers who may order screening CT and/or may discuss screening with patients.
|